TITLE:
Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

CONDITION:
Infections, Gram-Positive Bacterial

INTERVENTION:
Telavancin

SUMMARY:

      Serious infections caused by resistant bacteria are becoming more of a medical problem
      throughout the world. This study will measure how well TD-6424 (Telavancin) can control
      infections and whether the drug is safe to give to patients.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Patients must have a diagnosis of one of the following complicated skin and soft
             tissue infections and either a suspected or confirmed Gram positive organism

               -  major abscess requiring surgical incision and drainage

               -  infected burn (see exclusion criteria for important qualifications)

               -  deep/extensive cellulitis

               -  infected ulcer (see exclusion criteria for important qualifications)

               -  wound infection

          -  Patients must be expected to require at least 4 days of intravenous (IV) antibiotic
             treatment

        Exclusion Criteria:

          -  Previous systemic antibacterial therapy (with the exception of aztreonam and
             metronidazole) for > 24 hours within 7 days prior to the first dose of study drug
             unless the pathogen was resistant to prior treatment or the patient was a treatment
             failure (no clinical improvement after 3 days)

          -  Burns involving > 20% of body surface area or third degree/full thickness in nature,
             diabetic foot ulcers, ischemic ulcers/wounds, necrotizing fasciitis, gas gangrene, or
             mediastinitis
      
